Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention

Journal of the American College of Cardiology

Volumn 33, Issue 1, 1999, Pages 88-96

  Tardiff, Barbara E ^a   Califf, Robert M ^a   Tcheng, James E ^a   Michael Lincoff, A ^b   Sigmon, Kristina N ^a   Harrington, Robert A ^a   Mahaffey, Kenneth W ^a   Magnus Ohman, E ^a   Teirstein, Paul S ^c   Blankenship, James C ^d   Kitt, Michael M ^e   Topol, Eric J ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c SCRIPPS CLINIC   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; EPTIFIBATIDE; HEART ENZYME;

ADULT; AGED; ARTICLE; ATHERECTOMY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXCIMER LASER; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, LASER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATHERECTOMY, CORONARY; CORONARY DISEASE; CREATINE KINASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK; STENTS; TREATMENT OUTCOME;

EID: 0032941621     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00551-8     Document Type: Article

References (14)

1. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q-wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991;17:621-6.
2. Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994;74:748-54.
3. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25:1693-9.
4. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36.
5. Nicod P, Gilpin E, Dittrich H, et al. Short- and long-term clinical outcome after Q-wave and non-Q-wave myocardial infarction in a large patient population. Circulation 1989;79:528-36.
6. Madias JE, Gorlin R. The myth of acute "mild" myocardial infarction. Ann Intern Med 1977;86:347-52.
7. White RD, Grande P, Califf L, Palmeri ST, Califf RM, Wagner GS. Diagnostic and prognostic significance of minimally elevated creatine kinase-MB in suspected acute myocardial infarction. Am J Cardiol 1985;55: 1478-84.
8. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-6.
9. Ellis SG, Popma JJ, Buchbinder M, et al. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 1994;89:882-92.
10. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention-IMPACT-II. Lancet 1997;349:1422-8.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statit Assoc 1958;53:457-81.
12. Ferguson JJ, McDonough TJ, Worley SJ, et al., on behalf of the IMPACT-II Investigators. Clinical outcome of "high-risk" vs "elective" patients under-going percutaneous coronary intervention: results from IMPACT-II [abstract]. J Am Coll Cardiol 1996;27:180-1A.
13. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996;131:1097-1105.
14. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1996;330:956-61.